DelveInsight’s “Chemotherapy Induced Peripheral Neuropathy (CIPN) – Market Analysis Epidemiology Forecast to 2032” report delivers an in-depth understanding of the disease, historical and forecasted Chemotherapy Induced Peripheral Neuropathy (CIPN) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Some of the key facts of the Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Report:
Key Benefits of the Chemotherapy-Induced Peripheral Neuropathy (CIPN) Report:
Got queries? Click here to learn more about the Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Landscape
Chemotherapy-Induced Peripheral Neuropathy (CIPN) Overview
Cancer is a major cause of mortality worldwide and the number of deaths due to cancer is on the rise. In less than the last 20 years, cancer has emerged as the leading cause of mortality. And the number of cancer survivors is expected to increase in the coming years due to the increasing emergence of sensitive tests for detecting cancer and the administration of frontline chemotherapeutic agents. Chemotherapeutics are effective in arresting the progression of cancer because they are often designed to differentially target and eliminate rapidly dividing cancer cells.
Chemotherapy-induced peripheral neuropathy (CIPN) is a frequent, dose-dependent complication of anticancer drugs, including platinum, taxanes, epothilones, vinca alkaloids, and newer agents, such as bortezomib. It not only leads to dose reduction or discontinuation of treatment but also decreases the quality of life of cancer survivors. CIPN occurs in ~20% of patients given standard doses of chemotherapy and in almost 100% of patients treated with high doses.
Primary afferent neurons and their cell bodies located in the DRG are particularly vulnerable to the toxic effects of chemotherapy because they do not have a protective blood-brain barrier that is present in the CNS. Without the blood-brain barrier, substances in the blood can freely exchange across the walls of DRG and affect primary afferents. In cancer patients, this produces an array of sensory disturbances (e.g., numbness, tingling, burning, or dysesthesias) broadly known as CIPN that affects the hands and feet in a glove and stocking distribution. Patients typically present with symptoms consistent with CIPN weeks or months after beginning chemotherapy treatment.
Chemotherapy-Induced Peripheral Neuropathy (CIPN) Epidemiological Insights:
Chemotherapy Induced Peripheral Neuropathy (CIPN) Epidemiological Segmentation
Chemotherapy-Induced Peripheral Neuropathy (CIPN) Market Outlook
The Chemotherapy-Induced Peripheral Neuropathy (CIPN) market outlook of the report helps to build a detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand of better technology.
This segment gives a thorough detail of the market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
The market size of Chemotherapy Induced Peripheral Neuropathy (CIPN) in the G8 Countries is expected to increase at a CAGR of 2.94% for the study period (2016-2027). The expected launch of potential therapies may increase the market size in the coming years, assisted by an increase in the incident population of CIPN. Among the different classes of therapies that are currently prescribed to patients with CIPN, opioid analgesics is the most prescribed one that led to the highest market size among other classes. China accounts for the highest market size of CIPN in comparison to the United States, the EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan.
Learn more by requesting for sample @ Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Trends
Chemotherapy-Induced Peripheral Neuropathy (CIPN) Key Companies
Chemotherapy Induced Peripheral Neuropathy (CIPN) Therapies
Table of Contents
Click here to read more about Chemotherapy Induced Peripheral Neuropathy (CIPN) Market Insight
Related Reports
Chemotherapy Induced Peripheral Neuropathy (CIPN) Pipeline Insight, 2022
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Adya KaulEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/